Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Supreme Cannabis Company Inc. (The) T.FIRE

The Supreme Cannabis Co Inc is a Canada-based company engaged in the production and sale of medical and recreational cannabis. Its portfolio includes products that address recreational, medical, and wellness consumers. Its brands include BlissCo, Truverra, 7ACRES, Sugarleaf, and Hiway.

TSX:FIRE - Post Discussion

Supreme Cannabis Company Inc. (The) > LOAD UP ON CMED TRAIN BEFORE ITS TOO LATE
View:
Post by WarrenBuffettt on Jan 26, 2018 12:22pm

LOAD UP ON CMED TRAIN BEFORE ITS TOO LATE

As you all know the ACB/CMED merger is on the way.

The merger gives CMED shareholders 3.4 ACB shares per CMED share OR $5.70 cash plus 2.4 ACB shares per CMED share.

https://www.cannimedtherapeutics.com/investors/news/news-details/2018/Aurora-Cannabis-and-CanniMed-Therapeutics-Agree-to-Terms-on-Friendly-Transaction/default.aspx


"Under the New Offer, CanniMed shareholders may receive in respect of each CanniMed share, 3.40 Aurora shares or a combination of cash and shares at the election of each CanniMed Shareholder, subject to pro-ration with the maximum aggregate cash consideration of $140 million. Based on an implied Aurora share price of $12.65 and the 3.40 exchange ratio, the New Offer would equate to $43.00, representing a 181% premium over the closing price of CanniMed Shares on November 14, 2017, the last day prior to the public disclosure of Aurora’s intention to pursue a combination with CanniMed, and a 79% increase to the previous offer Cap Price of $24.00.

The total consideration for CanniMed under the New Offer is approximately $1.1 billion based on Aurora’s implied share price of $12.65. The maximum amount of cash available under the amended offer will be $140 million, and the number of Aurora shares to be issued will be between approximately 72 million (assuming full cash elections) and 84 million (assuming full share elections and no cash elections). Assuming maximum cash elections, each CanniMed shareholder would receive $5.70 in cash and 2.9493 Aurora shares."

To confirm I just got off the phone with investor realtions of both CMED and ACB
They said the conversion should happen fairly soon (could be next week)

Current Cmed price of 38.55 will give you ACB shares at $11.32 per share.


This will not last long.

Option 1.
$38.55CMED/3.4ACB= 3.4 ACB shares at $11.32

Option 2.
($38.55Cmed-$5.7Cash)/2.9ACB= 2.4 ACB shares at $11.32
Both scenarios offer a 17% discount on ACB shares
DONT MISS OUT AS THIS WONT LAST LONG

If you dont believe me call them yourself.

Their contact numbers on on their website

Comment by BirchBrook on Jan 26, 2018 3:12pm
These #'s aren't written in stone and will probably change, as it has already done from News Releases in the past. JMO. Until the agreement is signed,  no one knows what total dollar will be associated with each companies shares.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities